Several cancer genomics studies have identified USP20 mutation in a variety of solid tumors, including colorectal adenocarcinoma with a mutation frequency of 5.6% (4 out of 72 cases) (35), uterine corpus endometrioid carcinoma with 3.8% of cases mutated (9 out of 240 cases) (36) and bladder urothelial carcinoma with a mutation frequency of 3.1% (4 out of 127 cases) (37). This evidence concerns the gene USP20 and bladder transitional cell carcinoma.